Papp shared insights from the recent STRIDE phase 2 trial, which met all its primary and secondary endpoints. Data was presented at the American Academy of Dermatology Annual Meeting.
Kim Papp, MD, PhD, FRCPC
Advertisement
Articles by Kim Papp, MD, PhD, FRCPC
Advertisement
Latest Updated Articles
Kim Papp, MD, PhD, FRCPC: Exploring the Potential of ESK-001 in Plaque PsoriasisPublished: March 22nd 2024 | Updated:
Advertisement
Advertisement
Trending on Dermatology Times
1
Highlighting Ruxolitinib’s Role in Sustained Vitiligo Management
2
Derm Dispatch at SDPA Fall 2025: Elevating the Next Generation Through the Emerging Scholars Program
3
Clinical Tips for Managing Moderate to Severe Psoriasis With Systemics
4
Celebrating a 30 Year Legacy: Kristine Kucera, PA-C, MPAS, DHS, Receives SDPA Lifetime Achievement Award
5
